Cresco Labs Inc. (OTCMKTS:CRLBF) Given Average Rating of “Moderate Buy” by Brokerages

Cresco Labs Inc. (OTCMKTS:CRLBF) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $2.50.

A number of equities research analysts have issued reports on CRLBF shares. Atb Cap Markets lowered shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Roth Capital raised Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Finally, Cormark lowered Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th.

Cresco Labs Stock Down 5.1 %

Shares of OTCMKTS:CRLBF opened at $0.84 on Wednesday. The firm’s 50-day moving average is $0.92 and its two-hundred day moving average is $1.29. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39. Cresco Labs has a 1 year low of $0.78 and a 1 year high of $2.60. The firm has a market capitalization of $410.04 million, a PE ratio of -4.20 and a beta of 1.79.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.